HERZLIYA, Israel, Dec. 2, 2021 /PRNewswire/ -- Optibase Ltd. (NASDAQ: OBAS) today confirmed that it has received notice that The Capri Family Foundation, a foundation organized under the laws of the Republic of Panama (the "Bidder") and Shlomo (Tom) Wyler have commended an unsolicited tender offer to purchase 959,837 outstanding ordinary shares, nominal (par) value NIS 0.65 per share (the "Shares"), of Optibase Ltd. (the "Company"), not already owned by the Bidder group, at $11.20 per Share, net to the seller in cash, less any applicable withholding taxes, and without interest (the "Offer").
Search / 59 results found Showing: 1-10 of 59
BOZEMAN, Mont., Dec. 1, 2021 /PRNewswire/ -- FICO (NYSE:FICO), a leading predictive analytics and decision management software company, today announced Will Lansing, Chief Executive Officer, will present virtually at the Barclays Global Technology, Media and Telecommunications Conference on Wednesday, December 8th at 10:20 am EST.
NOVATO, Calif., Dec. 1, 2021 /PRNewswire/ -- Hennessy Advisors, Inc. (the "Company") (Nasdaq: HNNA) today announced that Lydia Knight-O'Riordan has been named to the Company's Board of Directors. Ms. Knight-O'Riordan brings fresh perspective, community involvement, and significant management experience to the Hennessy Board. She has gained a broad range of soft and technical skills as a project manager in her nearly four decades working for Hathaway Dinwiddie.
GERMANTOWN, Tenn., Dec. 1, 2021 /PRNewswire/ -- Mid-America Apartment Communities, Inc., or MAA (NYSE: MAA), today announced a full quarterly dividend of $1.0625 per outstanding share of its 8.50% Series I Cumulative Redeemable Preferred Stock. The dividend is payable on December 31, 2021, to shareholders of record on December 15, 2021.
SAN JOSE, Calif., Dec. 1, 2021 /PRNewswire/ -- Flex (NASDAQ: FLEX) announced today it has completed its previously announced $540 million all-cash acquisition of Anord Mardix, a global leader in critical power solutions, from private equity firm Bertram Capital. The acquisition strengthens Flex's Industrial business, adding to Flex's portfolio of power solutions and expanding its offerings in the rapidly growing data center market.
Senior U.S. District Court Judge Joseph F. Bataillon sentenced the 53-year-old woman to time served, or about 14 months. She will now serve three years of supervised release.
WARSAW, Ind., Nov. 30, 2021 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) (the "Company") today announced the pricing of the previously announced tender offers (collectively, the "Tender Offers" and each a "Tender Offer") to purchase for cash (i) any and all of its 3.700% Senior Notes due 2023 (the "Any and All Notes") and (ii) up to the aggregate purchase price set forth below (excluding accrued and unpaid interest up to, but not including, the applicable Settlement Date (as defined below) and excluding fees and expenses related to the Tender Offers) (the "Aggregate Maximum Purchase Price") of its 3.550% Senior Notes due 2025 (the "Acceptance Priority Level 1 Notes"), 3.550% Senior Notes due 2030 (the "Acceptance Priority Level 2 Notes"), 4.450% Senior Notes due 2045, 3.050% Senior Notes due 2026, 4.250% Senior Notes due 2035 and 5.750% Senior Notes due 2039 (collectively, the "Maximum Tender Offer Notes," and together with the Any and All Notes, the "Securities"). The Tender Offers are being made upon, and are subject to, the terms and conditions set forth in the Offer to Purchase dated November 15, 2021 (the "Offer to Purchase"), as amended by our press release of earlier today. Tenders of Securities may no longer be withdrawn except in certain limited circumstances where additional withdrawal rights are required by law.
NEW YORK, Nov. 30, 2021 /PRNewswire/ -- GreenLight Biosciences has partnered with the non-profit scientific research organization IAVI to work together on a Phase I clinical trial in Africa. IAVI and its partners were among the first to conduct HIV vaccine clinical trials in Africa, and since then, IAVI has sponsored more than 60 vaccine and biologics clinical trials in 13 countries. IAVI has built partnerships with centers of excellence for clinical research in five sub-Saharan African countries, and is developing vaccines and biologics against HIV, COVID-19, tuberculosis, Lassa fever, snakebite, and other diseases.